1 Metabolic alterations in human post-mortem frontal cortex and cerebrospinal fluid

2 associated with high levels of nicotine metabolite cotinine.

- 3 Wadzanai Masvosva¹, Marko Lehtonen¹, Mika Martiskainen^{2, 3}, Jari Tiihonen^{4, 5}, Pekka J.
- 4 Karhunen², Kati Hanhineva^{6, 7}, Jaana Rysä¹, Eloise Kok², and Olli Kärkkäinen^{1,}*
- ⁵ ¹ School of Pharmacy, University of Eastern Finland, Finland
- ⁶ ² Faculty of Medicine and Health Technology, Tampere University, Finland and Fimlab
- 7 Laboratories Ltd, Tampere University Hospital Region, Finland
- 8 ³ Finnish Institute for Health and Welfare, Finland
- ⁹ ⁴ Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital,
- 10 Finland
- ⁵ Department of Clinical Neuroscience, Karolinska Institutet and Center for Psychiatry
- 12 Research, Stockholm City Council, Stockholm, Sweden
- ⁶ Department of Life Technologies, Food sciences unit, University of Turku, Finland
- ⁷ School of Medicine, Institute of Public Health and Clinical Nutrition, University of Eastern
- 15 Finland, Finland
- 16
- 17 * Correspondence: Olli Kärkkäinen, olli.karkkainen@uef.fi, School of Pharmacy, University
- 18 of Eastern Finland, 70210 Kuopio, Finland

19

20 Ethics approval statement

- 21 The Tampere Sudden Death Study (TSDS) protocol was approved by the Ethics Committee
- of Pirkanmaa Hospital District (Permission number R09097) and the National Supervisory
- 23 Authority for Welfare and Health Valvira (Dnro 564/05.01.00.06/2010). This was in
- 24 accordance with the Declaration of Helsinki.

25 Data availability

- 26 The data that support the findings of this study are available on request from the
- 27 corresponding author, OK. The study plan approved by the ethical committee and the
- 28 participant consent terms preclude public sharing of these sensitive data, even in
- 29 anonymized form.

30 Funding statement

- 31 This study is funded by the Finnish Foundation for Alcohol Studies (OK), VTR funding (JT,
- 32 PJK), European Union 7th Framework Program grant number 201668 for AtheroRemo
- 33 Project (PJK), by State Research Funding for Tampere University Hospital (PJK), Pirkanmaa
- 34 Regional Fund of the Finnish Cultural Foundation (PJK), Finnish Cultural Foundation (EK),
- 35 Jane and Aatos Erkko Foundation (PJK, KH), Research Council of Finland (KH), and the
- 36 Finnish Foundation for Cardiovascular Research (PJK).

37 Conflict of Interest

- 38 OK and KH are founders of Afekta Technologies Ltd., a company offering metabolomics
- analysis services. Other authors report no potential conflicts of interest.

40 Acknowledgements

- 41 We thank Miia Reponen for the excellent technical assistance with the mass spectrometry
- 42 analyses. The authors want to thank Biocenter Finland and Biocenter Kuopio for
- 43 supporting their core LC-MS laboratory facility.

44 Abstract

45	Cigarette smoking is the single most significant cause of preventable death in the world.
46	Tobacco smoking causes exposure to thousands of chemicals and disrupts biological
47	pathways. It impacts several organs, including the brain, where its effects are mediated by
48	nicotinic acetylcholine receptors. Women seem to be more susceptible to the negative
49	health effects of smoking. In this study we focused on the changes in the metabolic profile
50	of human postmortem frontal cortex and cerebrospinal fluid samples associated with high
51	levels of the nicotine metabolite cotinine. We used non-targeted metabolomics to analyze
52	post-mortem frontal cortex and cerebrospinal fluid (CSF) samples from the Tampere
53	Sudden Death Study cohort. We identified 137 cases (24 females) with high cotinine levels,
54	indicating nicotine exposure. For controls, we identified 82 subjects (20 females) with no
55	cotinine in the frontal cortex or CSF samples and no known history of smoking based on
56	medical records and autopsy reports. Cases had significantly higher levels of 1-
57	methylhistamine (Cohen's d=0.66, p<0.0001) and N-acetylputrescine (d=0.84, p<0.0001),
58	and lower levels of aspartic acid (d=-0.53, p<0.001), 3-methylhistidine (d=-0.58, p=0.0004),
59	and taurine (d=-0.47, p=0.0002) in the frontal cortex compared to controls. Compared to
60	the frontal cortex, differences between cases and controls were smaller in the CSF samples.
61	Most of the observed differences were similar in both sexes, with a few exceptions like low
62	ergothioneine levels, observed especially in female cases. In conclusion, smoking or
63	nicotine exposure is associated with alterations in metabolites linked to increased oxidative

- 64 stress and neuroinflammation, as well as reduced neurotransmitter levels in the frontal
- 65 cortex.
- 66 Key words: tobacco, nicotine, smoking, metabolite profile.

67 Introduction

Cigarette smoking is the single most significant cause of preventable death in the world¹. 68 Tobacco smoking causes exposure to thousands of chemicals and can disrupt several 69 biological pathways, leading to negative health effects. A key component in tobacco is 70 nicotine, which is considered to be the main cause of addiction to tobacco smoking and is 71 currently also used in e-cigarettes, nicotine replacement products, and other tobacco-free 72 nicotine products². For example, nicotine is an important factor in the initiation and 73 progression of smoking-induced atherosclerosis³. Nicotine also dysregulates apoptosis 74 signaling pathways, which in turn initiates lung cell apoptosis and contributes to lung 75 diseases⁴. In human metabolism, nicotine is converted to cotinine that can be used to 76 assess recent nicotine exposure⁵. 77 78 Besides the heart and lungs, the brain is a target organ for nicotine, where its effects are mediated by nicotinic acetylcholine receptors⁶. Repeated long-term exposure to nicotine 79 alters the function of the brain. For example, it increases the levels of nicotinic 80 acetylcholine receptors, which in turn affects other neurotransmitter systems, including 81 glutamatergic and GABAergic systems⁷. Neuroimaging and neuropathological 82 83 investigations show a wide range of effects of nicotine exposure on the brain. Nicotine exposure has also been associated with damage to the endothelial cells, resulting in an 84 increased risk of cerebrovascular disease⁸. Smoking has been connected to structural 85 decreases in brain regions such as the right cerebellum, multiple prefrontal cortex regions 86

•	
88	implications, such as visual processing problems in the prefrontal cortex ⁹ .
89	Moreover, some of the effects of nicotine on the brain seem to differ between sexes ¹⁰ . For
90	example, when exposed to tobacco smoking, males show reduced left caudate volume with
91	altered functional connectivity, whereas females show a decreased right amygdala volume
92	and altered impulsivity correlations ¹¹ . However, possible sex differences in the metabolic
93	pathways of human brain are not known.

and the thalamus. This decrease in gray matter seems to have structural-behavioral

87

Non-targeted metabolomics is an excellent tool for measuring the effects of complex 94 chemical exposures, such as tobacco smoking. Non-targeted metabolomics measures 95 hundreds of endogenous, microbiota associated, and exogenous small molecules in a 96 sample and can therefore provide wide understanding of metabolic adaptations related to 97 different exposures¹². Smoking is associated with alterations in the circulating metabolite 98 profile¹³⁻¹⁷. Some of these changes could be important for brain function and may be 99 associated with nicotine dependence. For example, both tobacco smoking and use of 100 heated tobacco products have been linked with high blood levels of glutamate, the main 101 excitatory neurotransmitter^{14,16}. On the other hand, reduced blood levels of glutamate 102 seem to be an acute effect of cigarette smoking in current smokers¹⁵. Furthermore, levels 103 of another neurotransmitter, serotonin, has been reported to be increased in the blood in 104 current smokers¹³. However, circulating levels might not reflect levels in the brain¹⁸. 105 Understanding how tobacco smoking or nicotine exposure alters the brain metabolome 106 could be important for understanding brain related pathology associated with tobacco, 107

108	including nicotine	dependence.	However, n	o metabolomics	studies ha	ave been performed
-----	--------------------	-------------	------------	----------------	------------	--------------------

- to investigate the effects of tobacco smoking or nicotine exposure on human brain tissue.
- 110 Here, our aim was to investigate changes in the human brain and cerebrospinal fluid (CSF)
- 111 metabolite profiles associated with tobacco smoking or nicotine exposure. We conducted a
- 112 non-targeted metabolomics analysis using post-mortem frontal cortex and CSF samples to
- 113 gain novel insights into tobacco smoking or nicotine exposure-related changes in the
- 114 metabolic processes of the human brain. We also investigated possible sex-dependent
- 115 associations in the post-mortem samples.

116 Methods and Materials

117 Subjects

118	We used post-mortem frontal cortex and CSF samples from the Tampere Sudden Death
119	Study (TSDS) cohort ¹⁹ . The samples were collected from forensic autopsies on people who
120	suffered out-of-hospital deaths in the area of the Pirkanmaa Hospital District (Finland)
121	during 2010-2015. Frontal cortex (Broadman area 9) and CSF samples, a portion extracted
122	via syringe, were collected from a total of 700 subjects and stored at -80 $^\circ$ C until use.
123	The inclusion criteria for the current study cases were high cotinine (metabolite of nicotine)
124	levels in the CSF and frontal cortex samples. Smoking status, based on medical and
125	autopsy records, was missing from 64 cases (47%). Of those with a known smoking history,
126	most were tobacco smokers (69, 95%) and the rest smoked pipes or cigars. No cotinine in
127	the samples and no known history of smoking were inclusion criteria for the control group.
128	We excluded seven subjects who did not show smoking in medical records, but did have
129	high cotinine levels in frontal cortex or CSF samples. Furthermore, we excluded one subject
130	who was classified as a smoker based on medical records, but did not have any cotinine in
131	the frontal cortex or CSF samples. In the end, we had 137 subjects in the smoking group
132	and 82 in the control group (Table 1).

Variable	Controls	Cases	p-value
	(n=82)	(n=137)	
Age (years; mean±SD)	57 ± 14	53 ± 14	0.0627ª
Sex (Females, n (%))	20 (24%)	24 (18%)	0.2193 ^b
BMI (mean±SD)	30.4±6.8	28.5 ± 7.8	0.0548 ^a
PMI (days, mean±SD)	5.8 ± 2.5	5.3 ± 2.4	0.1592 ^a
Brain (grams, mean±SD)	1490 ± 139	1459 ± 151	0.1257ª
Cause of death (n (%))			0.4202 ^b
Accident	5 (6.1%)	4 (2.9%)	
Alcohol/drug poisoning	6 (7.3%)	20 (14.6%)	
Alcohol-related disease	7 (8.5%)	14 (10.2%)	
Cardiovascular disease	40 (48.8%)	50 (36.5%)	
Diabetes	3 (3.7%)	5 (3.6%)	
Suicide	10 (12.2%)	21 (15.3%)	
Other	10 (12.2%)	18 (13.1%)	
Unknown	1 (1.2%)	5 (3.6%)	

133 **Table 1:** Background characteristics

Table legend: ^a, Welch's t-test; ^b, χ2 test; BMI, body mass index; PMI, post-mortem interval.
 135

136 Non-targeted metabolomics analysis

137 The LC-MS analysis of the frontal cortex and CSF samples has been described in detail by

138 Kärkkäinen et al (2021)¹⁹. In brief, tissue samples were weighed with an added 80%

139 methanol (v/vH2O, LC-MS Ultra CHROMASOLV®, Fluka). 1000 µL solvent was added for

each 100 mg of frontal cortex tissue. For the CSF samples, 400 μl of acetonitrile (VWR

141 International, LC-MS grade) was added to 100 µL of CSF and mixed by pipette. Quality

142 control samples were made by taking 5 µL solution of each sample. The samples were

143 analyzed using a UHPLC-qTOF-MS system (Agilent Technologies, Waldbronn, Karlsruhe,

144 Germany). It consisted of a 1290 LC system, a jet stream electrospray ionization (ESI) source

and 6540 UHD accurate mass qTOF spectrometer. Samples were analyzed using two

146 chromatographic techniques, reversed-phase (RP, Zorbax Eclipse XDB-C18, particle size 1.8

147	μ m, dimensions of 2.1 × 100 mm, Agilent Technologies, USA) and hydrophilic interaction
148	(HILIC, Acquity UPLC BEH Amide 1.7 μm ,2.1 × 100 mm, Waters, Ireland), with both positive
149	and negative ionization. Quality control samples were injected at the beginning of the
150	analysis and at every 12 th sample. The analysis order of the samples was randomized.
151	Three different collision-induced dissociation voltages were used (10, 20, and 40 eV) for the
152	data-dependent tandem mass spectrometry (MSMS) analysis.
153	Metabolomics data-analysis was performed using MS-DIAL ver. 3.40 ²⁰ and Notame R-
154	package ²¹ . The peak picking and peak alignment parameters were: 1) mass range from 40
155	to 1000 (HILIC) or 1600 (RP) Da, MS tolerance 0.005 Da, MS2 tolerance 0.01 Da, minimum
156	peak width 10 scans, minimum peak height 10,000 (selected based on background noise

157 level). Peaks needed to be detected in at least 70% of samples from one study group to be

158 included in the final data matrix. Drift correction of the metabolomics data was done using

results from the QC sample, according to a previously published protocol²¹. In brief, the

160 molecular features were corrected for the drift pattern caused by the LC-MS procedures

using regularized cubic spline regression, fit separately for each feature on the QC samples.

162 The smoothing parameter was chosen from an interval between 0.5 and 1.5 using leave-

163 one-out cross-validation to prevent overfitting. After the drift correction, feature quality

164 was assessed, and low-quality features were flagged. Features were kept if their RSD* was

below 20% and their D-ratio below 40%. In addition, features with classic RSD, RSD*, and

166 basic D-ratio all below 10% were kept. This additional condition prevents the flagging of

167 features with very low values in all but a few samples. Missing values were imputed using

random forest imputation. QC samples were removed prior to imputation to prevent themfrom affecting the imputation.

170	Metabolite identification was focused on statistically significantly altered (see "statistical
171	analysis") molecular features. Metabolite identification was based on exact mass, isotopic
172	pattern, MS/MS fragmentation and retention time. Identifications were ranked according to
173	community guidelines ²² . Metabolites at level 1 were matched to an in-house library built
174	with chemical standards using the same experimental conditions. Level 2 includes
175	metabolites matching the exact mass and MSMS spectra from public libraries (METLIN,
176	LipidMaps, and Human Metabolome Database were used) or, in the case of lipids, the built-
177	in MS-DIAL library version 3.40. In level 3, only the chemical group of the compound (but
178	not the exact compound) is identifiable. Level 4 indicates unidentified compounds.

179 Statistical analysis

180 We used Welch's t-test (continuous variables) and χ^2 test (binomial variables) to evaluate differences between the study groups in background characteristics. We used Welch's t-test 181 and Cohen's d-effect sizes to evaluate differences between the study groups in the 182 metabolomics data. To estimate the possible role of sex, we performed additional analysis 183 separately for both sexes. To account for multiple testing, we adjusted the α level by the 184 number of principal components needed to explain 95% of the variation in the data. Here, 185 133 principal components were needed, and therefore the α level was adjusted to 0.0004. 186 187 P-values between 0.05 and 0.0004 were considered trends. For multivariate analysis, we

- used partial least squares discriminant (PLS-DA) analysis using SIMCA (v 17.0, Sartorius
- 189 Stedim Data Analytics Solutions) to calculate variable importance to projection (VIP) values.
- 190 Identified metabolites with p-value < 0.05 were correlated with PMI using Pearson's
- 191 method.

192 Results

193	The background characteristics (age, sex distribution, body mass index [BMI], post-mortem
194	interval [PMI], brain weight and causes of death) were similar between the study groups.
195	The cases in comparison to the controls, tended to be younger and slightly less overweight,

196 however, these differences did not reach statistical significance (Table 1).

197	In the metabolomics analysis, both frontal cortex and CSF samples showed differences
198	between the study groups in metabolite profiles (Figures 1-3, Supplementary Table S1). As
199	per the selection criteria, the nicotine metabolite cotinine was significantly higher in both
200	frontal cortex and CSF samples in the cases. In the frontal cortex, there were also higher
201	levels of N-acetylputrescine (Cohen's d = 0.84, p < 0.0001) and 1-methylhistamine (d = 0.66,
202	p < 0.0001), and lower levels of aspartic acid (d = -0.53, p = 0.0002) and 3-methylhistidine (d
203	= -0.58, p = 0.0004) in the cases compared to controls, which were statistically significant
204	after adjusting the α level for multiple testing. In the CSF samples, only the cotinine
205	difference between the study groups was significant at the multiple testing-corrected ${f lpha}$
206	level (0.0004). Furthermore, there were several other metabolites (e.g., amino acids,
207	xanthines and B-vitamins), which were lower in abundance in the cases as compared to the
208	controls in the frontal cortex (Figure 2) and CSF samples (Figure 3), with p-values between
209	0.05 and 0.0004. These findings should be considered trends.



Figure 1: The volcano plots show differences in the frontal cortex and CSF metabolite
profile between cases and controls. P-values (Welch's t-test), Cohen's d effect sizes and
variable importance for projection (VIP, from multivariate PLS-DA analysis) values of all
seen molecular features in post-mortem frontal cortex samples are shown in Fig. 1A, and
all molecular features in the cerebrospinal fluid samples are shown in Fig. 1B. Some
highlighted features were significantly altered between samples of the study groups
(multiple testing adjusted α level = 0.0004, Bonferroni's correction).



219 **Figure 2:** Differences between the study groups in the frontal cortex metabolome.

- 220 Individual values and group means ± 95% confidence intervals are shown. P-values from
- 221 Welch's t-test comparison between all cases and controls is shown as a number. P-values
- below 0.0004 are significant after correction for multiple testing and p-values between 0.05
- and 0.0004 should be considered trends. Welch's t-test comparisons between same sex
- 224 cases and controls (male cases vs. male controls, female cases vs. female controls) are
- shown with asterisks: *, p<0.05; **, p<0.01; ***, p<0.001. (Gray: control vs purple: case)



227



comparisons between same sex cases and controls (male cases vs. male controls, female
cases vs. female controls) are shown with asterisks: *, p<0.05; **, p<0.01; ***, p<0.001.
(Gray: control vs purple: case)

235

To estimate possible differences between sexes, we performed the statistical analysis 236 separately for both sexes. For all key findings, the direction of the difference in metabolite 237 238 levels between cases and controls remained the same (Supplementary Table S1). For most of the key findings, the Cohen's d effect size also remained at relatively similar levels, 239 although some metabolites did show a more pronounced difference between female cases 240 241 and controls (e.g., lower levels of ergothioneine, d = -1.06, and glutamate, d = -1.08, in the frontal cortex, and higher levels of leucic acid, d = 0.72, and glutamine, d = 0.69, in the CSF, 242 243 Supplementary Table S1). However, due to reduced statistical power, most p-values were > 244 0.05 in the comparison between the study groups when analyzing data only from female subjects. 245

Correlation analysis showed that in the frontal cortex, PMI was positively associated with aspartic acid (r = 0.225, p < 0.001), asparagine (r = 0.389, p < 0.001) and xanthine (r = 0.299, p < 0.001). In the CSF, PMI was positively associated with N-acetylglutamate (r = 0.256, p < 0.001) and negatively associated with LysoPE 22:5 (r = -0.276, p < 0.001, Supplementary Fig 1).

251 Discussion

252 The results of this study show that there are changes in the metabolite profiles of post-253 mortem human frontal cortex and CSF that are associated with exposure to tobacco or 254 nicotine products, as assessed by high levels of the nicotine metabolite cotinine in the 255 samples. Furthermore, most of the observed differences were similar in both sexes, with a 256 few exceptions, such as low ergothioneine levels observed especially in the female cases. As expected by study design, the tobacco or nicotine exposure-related metabolites were 257 significantly higher in the cases when compared to the controls. Previous studies have 258 shown that cotinine, a primary metabolite of nicotine, influences the neurotransmitters in 259 the frontal cortex and cerebrospinal fluid²³. For example, cotinine is effective in the 260 261 activation of the left prefrontal cortex in people who have guit smoking by enhancing the release of neurotransmitters like dopamine and serotonin, while smokers have reduced 262 activation, which has been linked to differing effects on cognitive processing due to 263 nicotine dependence²⁴. However, levels of most neurotransmitters degrade with PMI, 264 which can interfere with the interpretation of results from human post-mortem samples²⁵. 265 Glutamate and acetylcholine are generally more stable than serotonin and dopamine, but 266 they can still undergo changes depending on the PMI and storage conditions²⁵. 267 Furthermore, we observed low levels of taurine in the frontal cortex of the cases when 268 compared to the controls, in line with a previous report of decreased levels of taurine in 269

the brain samples of nicotine-exposed mice²⁶. In the brain, taurine plays a role in

271	antioxidative function, similar to the microbiota-associated metabolite ergothioneine,
272	which also showed a trend of low levels in the cotinine-positive group in the present
273	study ^{27,28} . In line with our results, low levels of ergothioneine have also been reported in
274	pregnant women who smoke ¹⁷ . These results suggest increased oxidative stress and
275	reduced antioxidative capacity in smoking- or nicotine-exposed brains.
276	Moreover, the cases had high levels of N-acetylputrescine in the frontal cortex samples
277	when compared to the controls. High N-acetylputrescine levels have been linked to, for
278	example, Parkinson's disease, glioblastoma and neurodevelopmental problems ^{29–32} . High
279	N-acetylputrescine levels could also be a marker of increased protein breakdown ³³ .
280	However, this does not seem to be the case here, since another proteolysis marker, 3-
281	methylhistidine, was significantly lower in the cases, and the average PMI was also lower in
282	the cases compared to controls. Therefore, more prolonged bodily degradation does not
283	explain the group difference of N-acetylputrescine.
284	Additionally, we observed high 1-methylhistamine (a brain-derived metabolite of histamine)
285	levels in the frontal cortex samples from the cases. Previously, high 1-methylhistamine
286	levels have been reported in young adults with a history of high alcohol use, where high 1-
287	methylhistamine levels were associated with low brain gray matter volume ³⁴ . High 1-
288	methylhistamine levels have been proposed to be associated with elevated histamine
289	levels and inflammatory processes in the brain ³⁵ .
290	Furthermore, the cases had low levels of aspartic acid in the frontal cortex compared to the
291	controls. In the brain, aspartic acid binds to NMDA receptors and is associated with

neuroplasticity³⁶. There were trends towards lower levels of other neurotransmitters, 292 293 namely glutamate and acetylcholine, in the frontal cortex samples of the cases. Overall, this suggests that the cases have altered neurochemistry compared to controls. This is 294 consistent with repeated chronic exposure to nicotine, which increases levels of nAChRs 295 and likely leads to a reduction in acetylcholine levels in the brain^{7,37,38}. Low levels of these 296 neurotransmitters in the frontal cortex could indicate altered neuroplasticity and activity in 297 298 the cases. Additionally, a previous study has reported that with nicotine exposure, acetylcholine levels were elevated in the striatum, and glutamate levels were reduced in 299 the hippocampus and striatum, but increased in the nucleus accumbens and prefrontal 300 cortex in mice²⁶. In humans, increased circulating levels of glutamate have been reported in 301 smokers^{14,16}. However, here we did not see an increase in CSF glutamate levels, and the 302 glutamate and acetylcholine levels were decreased in the frontal cortex. These results 303 indicate that the frontal cortex metabolome is, to some degree, independent of the levels 304 305 of these metabolites in the blood.

Moreover, we observed trends of decreased levels of several B-vitamins in cases compared to controls in the frontal cortex. Previously, low blood pantothenic acid (B5) is linked to smoking ¹³. These alterations could be due to diet, a notion which is supported by the trends of decreased levels of other metabolites associated with diet like proline betaine and theobromine, seen in the cases.

Limitations of the study include factors like smoking status not being available for allsubjects. Additionally, some high cotinine levels could be due to nicotine from other

sources, such as snuff or nicotine replacement therapy. Electronic cigarettes, nicotine 313 314 pouches, or similar products containing high levels of nicotine without tobacco for recreational use were not common in Finland during the period of sample collection (2010-315 2015). Therefore, it is presumed that most of the nicotine exposure leading to high cotinine 316 levels in this cohort is due to exposure to tobacco. Furthermore, these results are from a 317 single cohort with a relatively small number of subjects and therefore they should be 318 319 validated in a larger study with subjects from more diverse backgrounds. Even though there were no significant differences between cases and controls in PMI, some of the 320 results could be influenced by PMI. This is seen in the PMI correlation in the frontal cortex 321 with aspartic acid, asparagine, xanthine, and in the CSF with N-acetylglutamate and LysoPE 322 22:5. These post-mortem effects increase variation between samples, necessitating larger 323 sample sizes to observe exposure-related effects with adequate statistical power. Despite 324 these limitations, post-mortem samples provide a unique opportunity to obtain high-325 quality metabolomics data from the human brain¹⁹. Future studies should investigate how 326 327 the brain metabolome is altered in subjects exposed to nicotine-only-containing products. In conclusion, the current study successfully investigated changes in human post-mortem 328 frontal cortex and CSF metabolite profiles associated with tobacco smoking or nicotine 329 exposure. Cases had higher levels of metabolites associated with increased oxidative stress 330 331 and inflammation in the frontal cortex, and lower levels of neurotransmitters in the frontal cortex. Further studies are needed in several different populations, to broaden the reach of 332

these results.

334 **REFERENCES**

335

- Peacock A, Leung J, Larney S, et al. Global statistics on alcohol, tobacco and illicit drug
 use: 2017 status report. *Addiction*. 2018;113(10):1905-1926. doi:10.1111/add.14234
- Herman M, Tarran R. E-cigarettes, nicotine, the lung and the brain: multi-level cascading
 pathophysiology. *J Physiol*. 2020;598(22):5063-5071. doi:10.1113/JP278388
- Hahad O, Kuntic M, Kuntic I, Daiber A, Münzel T. Tobacco smoking and vascular biology and function: evidence from human studies. *Pflugers Arch*. 2023;475(7):797-805. doi:10.1007/s00424-023-02805-z
- Shen N, Gong T, Wang JD, et al. Cigarette smoke-induced pulmonary inflammatory
 responses are mediated by EGR-1/GGPPS/MAPK signaling. *Am J Pathol*. 2011;178(1):110 118. doi:10.1016/j.ajpath.2010.11.016
- Tan X, Vrana K, Ding ZM. Cotinine: Pharmacologically Active Metabolite of Nicotine and
 Neural Mechanisms for Its Actions. *Front Behav Neurosci*. 2021;15:758252.
 doi:10.3389/fnbeh.2021.758252
- Albuquerque EX, Pereira EFR, Alkondon M, Rogers SW. Mammalian nicotinic
 acetylcholine receptors: from structure to function. *Physiol Rev.* 2009;89(1):73-120.
 doi:10.1152/physrev.00015.2008
- Colyer-Patel K, Kuhns L, Weidema A, Lesscher H, Cousijn J. Age-dependent effects of
 tobacco smoke and nicotine on cognition and the brain: A systematic review of the
 human and animal literature comparing adolescents and adults. *Neurosci Biobehav Rev.* 2023;146:105038. doi:10.1016/j.neubiorev.2023.105038
- Chang RCC, Ho YS, Wong S, Gentleman SM, Ng HK. Neuropathology of cigarette
 smoking. *Acta Neuropathol*. 2014;127(1):53-69. doi:10.1007/s00401-013-1210-x
- Sutherland MT, Riedel MC, Flannery JS, et al. Chronic cigarette smoking is linked with
 structural alterations in brain regions showing acute nicotinic drug-induced functional
 modulations. *Behav Brain Funct*. 2016;12(1):16. doi:10.1186/s12993-016-0100-5
- 10. Cross SJ, Linker KE, Leslie FM. Sex-dependent effects of nicotine on the developing
 brain. J Neurosci Res. 2017;95(1-2):422-436. doi:10.1002/jnr.23878
- 11. Lin F, Han X, Wang Y, et al. Sex-specific effects of cigarette smoking on caudate and
 amygdala volume and resting-state functional connectivity. *Brain Imaging Behav*.
 2021;15(1):1-13. doi:10.1007/s11682-019-00227-z

- 12. Clish CB. Metabolomics: an emerging but powerful tool for precision medicine. *Cold Spring Harb Mol Case Stud.* 2015;1(1):a000588. doi:10.1101/mcs.a000588
- 368 13. Gu F, Derkach A, Freedman ND, et al. Cigarette smoking behaviour and blood
 369 metabolomics. *Int J Epidemiol*. 2016;45(5):1421-1432. doi:10.1093/ije/dyv330
- 14. Harada S, Ohmomo H, Matsumoto M, et al. Metabolomics profiles alterations in
 cigarette smokers and heated tobacco product users. *J Epidemiol*. Published online
 November 4, 2023. doi:10.2188/jea.JE20230170
- 15. Hsu PC, Lan RS, Brasky TM, et al. Metabolomic profiles of current cigarette smokers.
 Mol Carcinog. 2017;56(2):594-606. doi:10.1002/mc.22519
- 375 16. Xu T, Holzapfel C, Dong X, et al. Effects of smoking and smoking cessation on human
 376 serum metabolite profile: results from the KORA cohort study. *BMC Med*. 2013;11:60.
 377 doi:10.1186/1741-7015-11-60
- 17. Masvosva W, Voutilainen T, Lehtonen M, et al. Alterations in the plasma metabolome
 associated with maternal smoking during the first trimester. Published online
 November 29, 2024. doi:10.1101/2024.11.28.24318123
- 18. Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and
 therapeutics. *Annu Rev Pharmacol Toxicol*. 2009;49:57-71.
 doi:10.1146/annurev.pharmtox.48.113006.094742
- 19. Kärkkäinen O, Kokla M, Lehtonen M, et al. Changes in the metabolic profile of human
 male postmortem frontal cortex and cerebrospinal fluid samples associated with heavy
 alcohol use. *Addict Biol.* 2021;26(6):e13035. doi:10.1111/adb.13035
- 20. Tsugawa H, Cajka T, Kind T, et al. MS-DIAL: data-independent MS/MS deconvolution for
 comprehensive metabolome analysis. *Nat Methods*. 2015;12(6):523-526.
 doi:10.1038/nmeth.3393
- 21. Klåvus A, Kokla M, Noerman S, et al. "notame": Workflow for Non-Targeted LC–MS
 Metabolic Profiling. *Metabolites*. 2020;10(4):135. doi:10.3390/metabo10040135
- 392 22. Sumner LW, Amberg A, Barrett D, et al. Proposed minimum reporting standards for
 393 chemical analysis: Chemical Analysis Working Group (CAWG) Metabolomics Standards
 394 Initiative (MSI). *Metabolomics*. 2007;3(3):211-221. doi:10.1007/s11306-007-0082-2
- 395 23. Toth E, Sershen H, Hashim A, Vizi ES, Lajtha A. Effect of nicotine on extracellular levels of
 396 neurotransmitters assessed by microdialysis in various brain regions: role of glutamic
 397 acid. *Neurochem Res.* 1992;17(3):265-271. doi:10.1007/BF00966669

24. Ernst M, Matochik JA, Heishman SJ, et al. Effect of nicotine on brain activation during
performance of a working memory task. *Proc Natl Acad Sci U S A*. 2001;98(8):4728-4733.
doi:10.1073/pnas.061369098

- 401 25. Furczyk K, Schutová B, Michel TM, Thome J, Büttner A. The neurobiology of suicide A
 402 Review of post-mortem studies. *J Mol Psychiatry*. 2013;1(1):2. doi:10.1186/2049-9256-1-2
- 26. Li H, Chen B, Shao X, et al. 1H-Nuclear magnetic resonance-based metabolomic analysis
 of brain in mice with nicotine treatment. *BMC Neurosci*. 2014;15:32. doi:10.1186/14712202-15-32
- 406 27. Ahmed H, Leyrolle Q, Koistinen V, et al. Microbiota-derived metabolites as drivers of
 407 gut-brain communication. *Gut Microbes*. 2022;14(1):2102878.
 408 doi:10.1080/19490976.2022.2102878
- 28. Sener G, Ozer Sehirli A, Ipçi Y, et al. Taurine treatment protects against chronic nicotine-
- 410 induced oxidative changes. *Fundam Clin Pharmacol*. 2005;19(2):155-164.
 411 doi:10.1111/j.1472-8206.2005.00322.x
- 412 29. Jiang Z, Wang X, Zhang H, et al. Ketogenic diet protects MPTP-induced mouse model of
 413 Parkinson's disease via altering gut microbiota and metabolites. *MedComm (2020)*.
 414 2022;4(2):e268, doi:10.1002/mse2.268
- 414 2023;4(3):e268. doi:10.1002/mco2.268
- 415 30. Rodan LH, Anyane-Yeboa K, Chong K, et al. Gain-of-function variants in the ODC1 gene
- 416 cause a syndromic neurodevelopmental disorder associated with macrocephaly,
- 417 alopecia, dysmorphic features, and neuroimaging abnormalities. *Am J Med Genet A*.
- 418 2018;176(12):2554-2560. doi:10.1002/ajmg.a.60677
- 31. Saiki S, Sasazawa Y, Fujimaki M, et al. A metabolic profile of polyamines in parkinson
 disease: A promising biomarker. *Ann Neurol*. 2019;86(2):251-263. doi:10.1002/ana.25516
- 32. Wang DH, Fujita Y, Dono A, et al. The genomic alterations in glioblastoma influence the
 levels of CSF metabolites. *Acta Neuropathol Commun*. 2024;12(1):13.
 doi:10.1186/s40478-024-01722-1
- 424 33. Liu R, Li P, Bi CW, et al. Plasma N-acetylputrescine, cadaverine and 1,3-diaminopropane:
 425 potential biomarkers of lung cancer used to evaluate the efficacy of anticancer drugs.
 426 Oncotarget. 2017;8(51):88575-88585. doi:10.18632/oncotarget.19304
- 427 34. Heikkinen N, Kärkkäinen O, Laukkanen E, et al. Changes in the serum metabolite profile
 428 correlate with decreased brain gray matter volume in moderate-to-heavy drinking
 429 young adults. *Alcohol.* 2019;75:89-97. doi:10.1016/j.alcohol.2018.05.010
- 430 35. Carthy E, Ellender T. Histamine, Neuroinflammation and Neurodevelopment: A Review.
 431 *Front Neurosci.* 2021;15:680214. doi:10.3389/fnins.2021.680214

- 36. Jewett BE, Thapa B. Physiology, NMDA Receptor. In: *StatPearls*. StatPearls Publishing;
 2024. Accessed November 14, 2024. http://www.ncbi.nlm.nih.gov/books/NBK519495/
- 434 37. Moretti M, Mugnaini M, Tessari M, et al. A comparative study of the effects of the
- intravenous self-administration or subcutaneous minipump infusion of nicotine on the
- 436 expression of brain neuronal nicotinic receptor subtypes. *Mol Pharmacol.*
- 437 2010;78(2):287-296. doi:10.1124/mol.110.064071
- 438 38. Smart K, Naganawa M, Baldassarri SR, et al. PET Imaging Estimates of Regional
- 439 Acetylcholine Concentration Variation in Living Human Brain. *Cereb Cortex*.
- 440 2021;31(6):2787-2798. doi:10.1093/cercor/bhaa387

441

442